



10th Annual Symposium on Polycystic Kidney Disease

DRAFT Program

May 8th, 2017

The Joseph B. Martin Conference Center at Harvard Medical School (Bray Room) 77 Avenue Louis Pasteur, Boston, MA 02115

7:30 AM – 8:00 AM (Breakfast and Networking)

8:00 AM - 8:15 AM WELCOME AND OPENING REMARKS

Jing Zhou, MD, PhD, Brigham and Women's Hospital and Harvard Medical School Director, Harvard Center for Polycystic Kidney Disease Research

SESSION 1: UNDERSTANDING PKD AND CILIA Chairs:

8:15 AM – 8:45 AM **Questions to be answered in PKD** *Jing Zhou, MD, PhD, Brigham and Women's Hospital and Harvard Medical School*

8:50 AM – 9:20 AM What's new in intraflagellar transport and ciliogenesis Gregory Pazour, PhD, University of Massachusetts

9:25 AM – 9:55 AM **Ciliary signaling in tuberous sclerosis complex** Alessia Di Nardo, PhD, Boston Children's Hospital and Harvard Medical School

10:00 AM – 10:30 AM **Structure-function relationships in the ciliary Inversin compartment** *Peter Czarnecki, PhD, Brigham and Women's Hospital and Harvard Medical School*

10:30 AM – 11:00 AM (Photo and Coffee Break)

SESSION 2: PKD AND CILIARY SIGNALING Chairs:

11:00 AM – 11:30 AM Systems biology of polycystic kidney disease Jagesh V. Shah, PhD, Brigham and Women's Hospital and Harvard Medical School

11:30 AM – 12:00 AM

Ciliary signaling in epithelial-to-mesenchymal transition (EMT) and tumor-initiation *Vincent Guen, PhD, Massachusetts Institute of Technology*

12:00 AM – 12:30 AM **Mutations in MAPKBP1 cause cilia-independent nephronophthisis** *Friedhelm Hildebrandt, MD, Boston Children's Hospital and Harvard Medical School*

12:30 PM - 1:30 PM (Lunch Break)

SESSION 3: DISEASE MODELING, HUMAN CLINICAL TRIALS Chairs:

1:30 PM – 2:00 PM **Mitochondrial dysfunction in ADPKD** *Thomas Natoli, MD, Sonofi Genzyme*

2:00 PM – 2:30 PM **Multi-targeted tyrosine kinase inhibitor: results from a 3-year trial** *Theodore Steinman, MD, Beth Israel Deaconess Medical Center and Harvard Medical School*

2:30 PM – 3:00 PM **Kidney organoids: modeling polycystic kidney disease** *Ryuji Morizane, PhD, Brigham and Women's Hospital and Harvard Medical School*

3:00 PM - 3:20 PM (Break)

SESSION 4: DISEASE MODELING, INTERVENTIONS Chairs:

3:20 PM – 3:50 PM **A new therapeutic target in the mTOR pathway** *Hilaire Lam, PhD, Brigham and Women's Hospital and Harvard Medical School*

3:50 PM – 4:20 PM **TAME PKD clinical trial of metformin in ADPKD** *Ronald Perrone, MD, Tufts University Medical Center*

Keynote Lecture 4:20 PM – 5:00 PM Transcriptional and posttranscriptional control in polycystic kidney disease Peter Igarashi, MD, University of Minnesota

CLOSING REMARKS Jing Zhou, MD, PhD, Director, Harvard Center for Polycystic Kidney Disease Research